Campbell Chelsea N, Krantz Matthew S, Yu Alexis, Phillips Elizabeth J
medRxiv. 2025 May 25:2025.05.23.25328236. doi: 10.1101/2025.05.23.25328236.
Carriage of HLA-B*58:01 has been shown to have a strong association with the development of allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) and drug reaction and eosinophilia and systemic symptoms (DRESS) in many populations globally; however, there is a critical need to determine if this is generalizable to varying populations including those in the United States (US).
To perform HLA class I and II association studies in a cohort of US patients diagnosed with allopurinol-induced SJS/TEN or DRESS compared to allopurinol tolerant and population controls.
We enrolled consenting individuals who had specialist adjudicated allopurinol-induced SJS/TEN or DRESS (collectively allopurinol-SCAR). HLA carriage in these cases was compared to allopurinol tolerant and population controls identified through Vanderbilt University Medical Center (VUMC) BioVU, a biobank which includes 94,489 individuals with imputed human leukocyte antigen (HLA) class I and II typing from genotyping array data.
We performed HLA class I and II conditional logistic regression case-control analyses between allopurinol-SCAR cases and both population controls and allopurinol tolerant controls matched on age, sex, and self-identified race. We reported odds ratio (OR) and 95% confidence interval (CI) with Bonferroni corrected ( ) <.05.
The conditional logistic regression analyses included allopurinol-SCAR cases (n=16) and 10:1 matched allopurinol tolerant controls (n=160). We found two HLA class I alleles independently associated with increased risk of allopurinol-induced SCAR: HLA-B58:01 (OR 28 [95% CI, 8.6 - 100.6]) and HLA-A34:02 (OR 20.6 [95% CI, 3.3 - 131.1]). We did not identify any HLA class II alleles meeting the Pc level of significance.
We found HLA-B58:01 to be strongly associated with allopurinol-induced SCAR, generalizing findings from previous studies. Additionally, we found HLA-A34:02 to be a second independent genetic risk factor for allopurinol-SCAR. These findings underscore the need to conduct specific population-based studies that both reproduce known and uncover novel HLA associations in order to reduce harm through contributions to screening, risk stratification, and diagnosis.
Is the association between HLA-B58:01 and allopurinol-SCAR generalizable to admixed populations in the US or are additional HLA associations involved? In this HLA association study with 16 patients of primarily self-identified Black race of adjudicated allopurinol-induced SJS/TEN or DRESS, we demonstrate a strong association with the established risk allele, HLA-B58:01, and, for the first time, identified HLA-A34:02 as an additional independent risk factor. HLA-B58:01 is absent in more than one-third of our US cohort of allopurinol-SCAR cases suggesting that more comprehensive screening and diagnostic approaches are necessary to prevent additional cases in genetically heterogenous populations.
在全球许多人群中,携带HLA - B*58:01已被证明与别嘌醇诱导的史蒂文斯 - 约翰逊综合征和中毒性表皮坏死松解症(SJS/TEN)以及药物反应伴嗜酸性粒细胞增多和全身症状(DRESS)的发生密切相关;然而,迫切需要确定这一现象是否适用于包括美国人群在内的不同人群。
在美国被诊断为别嘌醇诱导的SJS/TEN或DRESS的患者队列中,与别嘌醇耐受者及人群对照进行HLA I类和II类关联研究。
设计、地点和参与者:我们招募了经专科医生判定为别嘌醇诱导的SJS/TEN或DRESS(统称为别嘌醇 - SCAR)的同意参与研究的个体。将这些病例的HLA携带情况与通过范德比尔特大学医学中心(VUMC)BioVU识别出的别嘌醇耐受者及人群对照进行比较,BioVU是一个生物样本库,包含94489名根据基因分型阵列数据推算出人类白细胞抗原(HLA)I类和II类分型的个体。
我们在别嘌醇 - SCAR病例与人群对照以及年龄、性别和自我认定种族相匹配的别嘌醇耐受对照之间进行了HLA I类和II类条件逻辑回归病例对照分析。我们报告了经Bonferroni校正(P<0.05)的优势比(OR)和95%置信区间(CI)。
条件逻辑回归分析纳入了别嘌醇 - SCAR病例(n = 16)和10:1匹配的别嘌醇耐受对照(n = 160)。我们发现两个HLA I类等位基因与别嘌醇诱导的SCAR风险增加独立相关:HLA - B58:01(OR 28 [95% CI,8.6 - 100.6])和HLA - A34:02(OR 20.6 [95% CI,3.3 - 131.1])。我们未发现任何达到Pc显著性水平的HLA II类等位基因。
我们发现HLA - B58:01与别嘌醇诱导的SCAR密切相关,这一结果推广了先前研究的发现。此外,我们发现HLA - A34:02是别嘌醇 - SCAR的第二个独立遗传风险因素。这些发现强调了开展基于特定人群的研究的必要性,这类研究既能重现已知的HLA关联,又能发现新的关联,以便通过为筛查、风险分层和诊断提供帮助来减少危害。
HLA - B58:01与别嘌醇 - SCAR之间的关联是否适用于美国的混合人群,还是涉及其他HLA关联?在这项针对16名主要自我认定为黑人种族、经判定为别嘌醇诱导的SJS/TEN或DRESS患者的HLA关联研究中,我们证明了与既定风险等位基因HLA - B58:01存在强关联,并且首次将HLA - A34:02鉴定为另一个独立风险因素。在我们的美国别嘌醇 - SCAR病例队列中,超过三分之一的病例不存在HLA - B58:01,这表明在遗传异质性人群中,需要更全面的筛查和诊断方法来预防更多病例。